Company: LENZ
Filing Date: 2025-03-19
Form Type: 10-K
Source: 0001815776-25-000019
Chunk: 29

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-03-19
Form: 10-K
Item: Item 9B
Chunk 29
---
employee director may be provided cash retainers or fees and granted awards with values with amounts that, in any fiscal year, in the aggregate, exceed $750,000, provided that, in the fiscal year containing a non-employee director's Initial Start Date, such limit will be increased to $1,000,000. Any awards or other compensation provided to an individual (a) for his or her services as an employee, or for his or her services as an advisor or consultant other than as a non-employee director, or (b) prior to the closing of the Merger, will be excluded for purposes of the foregoing limit.

Director Compensation for Fiscal Year 2024

The following table sets forth information regarding the compensation earned for service on our board of directors during the year ended December 31, 2024 by non-employee directors. Mr. Schimmelpennink did not receive any additional compensation for his service as a director in 2024. Mr. Schimmelpennink's compensation as a named executive officer, and Ms Drapkin's compensation received as a non-employee director since the closing of the Merger, is set forth below under “— Summary Compensation Table.”

NameFees earned or paid in cash ($)Option awards ($)(1)All other compensation ($)Total ($)Jeff George(2)62,418 333,804 — 396,222 Frederic Guerard(3)46,423 333,804 — 380,227 James McCollum(4)31,209 333,804 — 365,013 Shelley Thunen(5)47,593 333,804 — 381,397 Zach Scheiner(6)40,962 333,804 — 374,766 Abraham Bassan(7)11,250 — — 11,250 Jerel Davis(7)11,625 — — 11,625 Kristin M. Hege(7)11,250 — — 11,250 Joseph Jimenez(7)11,625 — — 11,625 Perry Karsen(7)19,500 — — 19,500 Matthew Porteus(7)10,000 — 17,500 (8)27,500 Carlo Rizzuto(7)11,250 — — 11,250 S